News & meetings
Consortium Meeting, June 2017
The project team met in Rome, Italy, for a first joint progress review meeting.
Start of enrolment – first project clinical study
The First Pacient First Visit (FPFV) milestone was achieved on 9th November 2017. This 2-week EBA study aims to identify a suitable combination of β-lactam antibiotics to treat Tuberculosis.
Consortium Meeting, February 2018
The project team met in Tromso, Norway, for a two-days project meeting. We discussed progress, milestones achieved, implementation difficulties and alternatives moving forward.
End of the first Reporting Period
We reported progress, activities and costs to the EU after the first 18 project months.
Consortium Meeting, February 2019
The project team met in Cape Town, South Africa for a progress review meeting. We also visited the project clinical sites and a hospital in the area.
Start of enrolment – second project clinical study
The First Pacient First Visit (FPFV) milestone was achieved on 27th March 2019. This 2-week EBA study aims to establish proof of concept of anti-TB efficacy in humans of a low-dose oxaborole drug.
Consortium Meeting, July 2019
The project team met in Castelldefels, Spain, coinciding with the Tuberculosis Drug Discovery and Development Gordon Research Conference.
Mid-term review, September 2019
We discussed project progress and plans moving forward with our EU Project Officer.
Grant Agreement amendment
The global TB pipeline is progressing fast and new knowledge and results are being published. The project team reviewed the work plan and requested a GA amendment to maximize the project impact.
End of the second Reporting Period
We reported progress, activities and costs to the EU after 36 months of activity.
Consortium Meeting, May 2020
The project team met by videoconference to discuss project progress and next steps. Our original plan to meet face-to-face in Hamburg was postponed due COVID-19 related mobility restrictions, which are also affecting several project activities.
Consortium Meeting, October 2020
The project team met by videoconference due COVID-19 related mobility restrictions. The consortium reviewed progress and timelines, including the possibility of requesting a no-cost extension to complete the planned deliverables. The final decision will be made in 2021.